Type 2 Diabetes Risk Screening

Type 2 diabetes risk screening is the testing of asymptomatic people for elevated blood glucose — including prediabetes and undiagnosed diabetes — using measures such as fasting plasma glucose, glycated haemoglobin (HbA1c), or oral glucose tolerance testing. Because dysglycaemia develops silently and raises the risk of cardiovascular and microvascular disease, early detection is a recurring aim of preventive care.

Definition

Type 2 diabetes risk screening is the application of glycaemic tests — fasting glucose, HbA1c, or glucose tolerance testing — to asymptomatic individuals in order to detect prediabetes or previously undiagnosed type 2 diabetes.

Scope

The entry covers the rationale for screening for prediabetes and type 2 diabetes, the glycaemic measures used, the concept of risk-based or age-based screening eligibility, and the relationship between dysglycaemia and cardiovascular risk. It is a reference description of the screening concept and supporting evidence, not a protocol for ordering tests, setting diagnostic cut-points, or treating any individual.

Core questions

• Who should be screened for prediabetes and type 2 diabetes, and from what age or risk level?
• Which glycaemic tests are used for screening, and how do they differ?
• Does detecting and treating screen-detected diabetes earlier improve outcomes?

Key concepts

• Fasting plasma glucose
• Glycated haemoglobin (HbA1c)
• Oral glucose tolerance test
• Prediabetes (impaired fasting glucose / impaired glucose tolerance)
• Risk-based and age-based screening eligibility
• Dysglycaemia as a cardiovascular risk factor

Mechanisms

Type 2 diabetes is preceded by a long, asymptomatic phase of rising insulin resistance and impaired glucose handling, during which glucose levels can be detected by laboratory measures before symptoms appear. Screening uses fasting plasma glucose, HbA1c (which reflects average glycaemia over weeks to months), or glucose tolerance testing to identify prediabetes and undiagnosed diabetes. Detecting dysglycaemia matters not only for diabetes itself but because it contributes to cardiovascular risk, linking this screening to the broader cardiometabolic assessment (Visseren et al., 2021).

Clinical relevance

Diabetes screening supports primary prevention and early management within preventive care. This entry describes the screening concept and its evidence base; it characterizes how dysglycaemia is detected at the population level and is not a guide to diagnosing or treating an individual.

Epidemiology

Type 2 diabetes and prediabetes are highly prevalent and rising globally, and a substantial proportion of cases are undiagnosed, which is the central rationale for screening at-risk or older adults (USPSTF, 2021). Dysglycaemia is also a recognized contributor to the global burden of cardiovascular disease.

Evidence & guidelines

The US Preventive Services Task Force recommends screening for prediabetes and type 2 diabetes in adults within a defined age and weight range (USPSTF, 2021), and the American Diabetes Association Standards of Care describe the glycaemic tests and diagnostic criteria used (ADA, 2024). Trial evidence such as ADDITION-Europe examined cardiovascular outcomes after screen-detection and early treatment (Griffin et al., 2011), and cardiovascular prevention guidelines situate dysglycaemia within total risk (Visseren et al., 2021).

History

Glucose-based detection of diabetes evolved from glucose tolerance testing toward fasting glucose and, more recently, HbA1c as a standardized screening and diagnostic measure (ADA, 2024). Screening of asymptomatic at-risk adults was consolidated in guideline recommendations as the silent, high-prevalence nature of prediabetes and undiagnosed diabetes became clear (USPSTF, 2021).

Debates

Does screen-detection of type 2 diabetes improve long-term outcomes?

The ADDITION-Europe trial found that intensive early treatment of screen-detected diabetes produced only modest, non-significant differences in cardiovascular endpoints over five years, prompting ongoing discussion about how much screening alone changes hard outcomes.

Seminal works

• uspstf-dm-2021
• ada-2024-dx
• griffin-2011

Frequently asked questions

Which tests are used to screen for type 2 diabetes?

Screening commonly uses fasting plasma glucose, glycated haemoglobin (HbA1c), or an oral glucose tolerance test, each of which can detect prediabetes or undiagnosed diabetes in people without symptoms.

Why screen for diabetes before symptoms appear?

Type 2 diabetes has a long silent phase during which glucose abnormalities are detectable, and earlier detection allows prevention efforts; it is also relevant because dysglycaemia contributes to cardiovascular risk.